Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 29, 2024 1:06pm

80 Views

Post# 36201507

RE:RE:RE:RE:RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

May 2024 - The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer:

while ICI monotherapy has limited efficacy in MSS CRC, combination strategies hold promise to enhance survival outcomes

n 2021 Titto Augustine, Sanjay Goel, et al. found for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. They reported that their data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the expression of PD-L1 marker on respective target cells.

Combinatorial treatment activated the innate immune system, pattern recognition receptors, and antigen presentation markers. Furthermore, the investigators observed the reduction of immunosuppressive macrophages and expansion of effector T cell subsets, as well as reduction in T cell exhaustion. The current investigation sheds light on the immunological mechanisms of the reovirus-anti-PD-1 combination to reduce the growth of MSS CRC.

https://academic.oup.com/oncolo/article/29/5/e580/7600404

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta